Toxoplasmosis Treatment Market

Reports

📃Pages:
110

📊Tables:
91

📈Charts:
61

🌐Regions/Countries:
4 / 10

🏢Companies:
10

📨Enquiry Hours:
10

Toxoplasmosis is an infection caused due to a common parasite, which is present in cat feces and in contaminated food. This parasite is referred as Toxoplasma gondii. The symptoms of toxoplasmosis disease are headache, body aches and pain, fever, fatigue, and swollen lymph nodes. Apart from this, the people with weakened immune system who receive chemotherapy, a preceding toxoplasma infection may arise and cause the symptoms such as confusion, poor coordination, headache, and seizures. The growing prevalence of toxoplasmosis is the key factor propelling the market growth.

The incidence of toxoplasmosis is on the rise, majorly owing to the rise in the number of people with low immune systems, such as cancer patients, HIV/AIDS patients, and transplant recipients. This is propelling the demand for effective treatments for the disease. In addition to this, the rise in awareness about foodborne illness accelerates the growth of toxoplasmosis treatment market. On the other hand, the negative effects of the drugs may negatively impact the toxoplasmosis treatment market growth. The Toxoplasmosis Treatment Market is expected to grow at a rate of 4.3% CAGR by 2027.

Toxoplasmosis Treatment Market by Type:

Acquired Toxoplasmosis
Congenital Toxoplasmosis

Toxoplasmosis Treatment Market by Route of Administration:

Oral
Parenteral

Toxoplasmosis Treatment Market by Distribution Channel:

Hospital Pharmacies
Drug Stores and Retail Pharmacies
Online Providers

Toxoplasmosis Treatment Market by Geography:

North America
Europe
Asia Pacific
Rest of the World

As in the Toxoplasmosis Treatment market for type is segmented into acquired toxoplasmosis and congenital toxoplasmosis. The acquired toxoplasmosis segment has acquired a significant share in the market. This is due to the increase in incidence of parasitic infection which causes acquired toxoplasmosis. Further, the congenital toxoplasmosis segment is anticipated to register highest CAGR over the forecast period.

On the basis of route of distribution segmentation the Toxoplasmosis Treatment market is bifurcated into Oral and Parenteral. Compared to parenteral, the oral segment dominated the market with highest share. This can be attributed to the increased adoption of oral drugs owing to noninvasive, high patient compliance, easy to handle, and does not need any specific sterile conditions.

In terms of distribution channel, the market is divided into Hospital Pharmacies, Drug Stores and Retail Pharmacies and Online Providers. The hospital pharmacies segment holds the maximum share of the market. The maximum share of the segment is ascribed to the availability of toxoplasmosis drugs and increase in number of hospital pharmacies to treat the toxoplasmosis disease.

In accordance to the regional analysis, the market is segmented into North America, Europe, Asia Pacific and Rest of the World. The North America region is anticipated to lead the market due to the presence of leading players, increase in government initiatives, well-developed healthcare infrastructure, and rise in occurrence of cancer disease which causes toxoplasmosis.

In addition, the healthcare organizations, governments, and non-profit organizations across the world are working to raise awareness regarding the dangers of toxoplasmosis disease and the prominence of early diagnosis and treatment. This is resulting in more people looking for medical attention and accelerating the demand for effective treatments. Thus, the rising awareness regarding the toxoplasmosis disease is vitally driving the global market growth. Apart from this, the increase in chemotherapy procedures can result in growth in number of toxoplasmosis infection, therefore, this highlights the requirement for the toxoplasmosis treatment for the patient, leading to the growth of the market.

Prominent players of the toxoplasmosis treatment market are Teva Pharmaceutical Industries Limited, Mangalam Drugs and Organics Ltd., Zorish Healthcare Private Limited, Alvogen, Dr Reddy’s Laboratories Ltd., Vyera Pharmaceuticals LLC, Oakrum Pharma, Kaiser Permanente, omicron pharmaceuticals, and Manus Aktteva Biopharma LLP.

Henceforth, now-a-days the trend of pets in home is rising highly which leads to the increased pets related diseases among humans. Thus, this factor is majorly leading to the increased occurrence of toxoplasmosis disease in humans which eventually contributes to growth of the market growth.

This study represents the key manufacturers, presenting of sales, revenue, market size and new developments for major players.
This study analyzes the global and key geographical regions market prospective and advantages, opportunities and challenges, constraints and risks.
This report further depicts the important trends, drivers, impacting factors of the toxoplasmosis treatment
This report represents the competitive outlook in terms of expansions, agreements, new product launches and acquisitions in the toxoplasmosis treatment

Additional information

User License	Single User, Multi User, Enterprise

Table Of Content

Executive Summary
Industry Outlook
- Industry Overview
- Industry Trends
Market Snapshot
- Market Definition
- Market Outlook
  - Porter Five Forces
- Related Markets
Market characteristics
- Market Overview
- Market Segmentation
- Market Dynamics
  - Drivers
  - Restraints
  - Opportunities
- DRO – Impact Analysis
Type: Market Size & Analysis
- Overview
- Acquired Toxoplasmosis
- Congenital Toxoplasmosis
Route of Administration: Market Size & Analysis
- Overview
- Oral
- Parenteral
Distribution Channel: Market Size & Analysis
- Overview
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Providers
Geography: Market Size & Analysis
- Overview
- North America
- Europe
- Asia Pacific
- Rest of the World
Competitive Landscape
- Competitor Comparison Analysis
- Market Developments
  - Mergers and Acquisitions, Legal, Awards, Partnerships
  - Product Launches and execution

Vendor Profiles
- Teva Pharmaceutical Industries Limited
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Mangalam Drugs and Organics Ltd.
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Zorish Healthcare Private Limited
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Alvogen
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Dr Reddy’s Laboratories Ltd.
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Vyera Pharmaceuticals LLC
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Oakrum Pharma
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Kaiser Permanente
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- omicron pharmaceuticals
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy
- Manus Aktteva Biopharma LLP
  - Overview
  - Financial Overview
  - Product Offerings
  - Developments
  - Business Strategy

Analyst Opinion
Annexure
- Report Scope
- Market Definitions
- Research Methodology
  - Data Collation and In-house Estimation
  - Market Triangulation
  - Forecasting
- Report Assumptions
- Declarations
- Stakeholders
- Abbreviations

Methodology

Infoholic Research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

Data Collation (Primary & Secondary)
In-house Estimation (Based on proprietary data bases and Models)
Market Triangulation
Forecasting

List of Tables

TABLE 1. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 2. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ACQUIRED TOXOPLASMOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 3. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR CONGENITAL TOXOPLASMOSIS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 4. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 5. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ORAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 6. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR PARENTERAL, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 7. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 8. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR HOSPITAL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 9. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR DRUG STORES AND RETAIL PHARMACIES, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 10. GLOBAL TOXOPLASMOSIS TREATMENT MARKET VALUE FOR ONLINE PROVIDERS, BY GEOGRAPHY, 2021-2027 (USD BILLION)

TABLE 11. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 12. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 13. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 14. NORTH AMERICA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 15. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 16. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 17. U.S TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 18. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 19. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 20. CANADA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 21. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 22. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 23. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 24. EUROPE TOXOPLASMOSIS TREATMENT MARKET VALUE, DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 25. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 26. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 27. GERMANY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 28. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 29. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 30. U.K TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 31. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 32. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 33. FRANCE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 34. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 35. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 36. ITALY TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 37. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 38. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 39. SPAIN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 40. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 41. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 42. ROE TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 43. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY COUNTRY, 2021-2027 (USD BILLION)

TABLE 44. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 45. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 46. ASIA PACIFC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 47. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 48. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 49. CHINA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 50. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 51. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 52. INDIA TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 53. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 54. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 55. JAPAN TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 56. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 57. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 58. REST OF APAC TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 59. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY TYPE, 2021-2027 (USD BILLION)

TABLE 60. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2021-2027 (USD BILLION)

TABLE 61. REST OF WORLD TOXOPLASMOSIS TREATMENT MARKET VALUE, BY DISTRIBUTION CHANNEL, 2021-2027 (USD BILLION)

TABLE 62. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: FINANCIALS

TABLE 63. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCTS & SERVICES

TABLE 64. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: RECENT DEVELOPMENTS

TABLE 65. MANGALAM DRUGS AND ORGANICS LTD.: FINANCIALS

TABLE 66. MANGALAM DRUGS AND ORGANICS LTD.: PRODUCTS & SERVICES

TABLE 67. MANGALAM DRUGS AND ORGANICS LTD.: RECENT DEVELOPMENTS

TABLE 68. ZORISH HEALTHCARE PRIVATE LIMITED: FINANCIALS

TABLE 69. ZORISH HEALTHCARE PRIVATE LIMITED: PRODUCTS & SERVICES

TABLE 70. ZORISH HEALTHCARE PRIVATE LIMITED: RECENT DEVELOPMENTS

TABLE 71. ALVOGEN: FINANCIALS

TABLE 72. ALVOGEN: PRODUCTS & SERVICES

TABLE 73. ALVOGEN: RECENT DEVELOPMENTS

TABLE 74. DR REDDY’S LABORATORIES LTD.: FINANCIALS

TABLE 75. DR REDDY’S LABORATORIES LTD.: PRODUCTS & SERVICES

TABLE 76. DR REDDY’S LABORATORIES LTD.: RECENT DEVELOPMENTS

TABLE 77. VYERA PHARMACEUTICALS LLC: FINANCIALS

TABLE 78. VYERA PHARMACEUTICALS LLC: PRODUCTS & SERVICES

TABLE 79. VYERA PHARMACEUTICALS LLC: RECENT DEVELOPMENTS

TABLE 80. OAKRUM PHARMA: FINANCIALS

TABLE 81. OAKRUM PHARMA: PRODUCTS & SERVICES

TABLE 82. OAKRUM PHARMA: RECENT DEVELOPMENTS

TABLE 83. KAISER PERMANENTE: FINANCIALS

TABLE 84. KAISER PERMANENTE: PRODUCTS & SERVICES

TABLE 85. KAISER PERMANENTE: RECENT DEVELOPMENTS

TABLE 86. OMICRON PHARMACEUTICALS: FINANCIALS

TABLE 87. OMICRON PHARMACEUTICALS: PRODUCTS & SERVICES

TABLE 88. OMICRON PHARMACEUTICALS: RECENT DEVELOPMENTS

TABLE 89. MANUS AKTTEVA BIOPHARMA LLP: FINANCIALS

TABLE 90. MANUS AKTTEVA BIOPHARMA LLP: PRODUCTS & SERVICES

TABLE 91. MANUS AKTTEVA BIOPHARMA LLP: RECENT DEVELOPMENTS